Natural Management

Evidence Review

Ashwagandha (KSM-66)

Chandrasekhar et al. (2012) conducted a 60-day randomized, double-blind, placebo-controlled trial in 64 adults with a history of chronic stress. Participants receiving 300 mg KSM-66 root extract twice daily showed a 44% reduction in Perceived Stress Scale scores compared to 5.5% in the placebo group (p<0.0001). Serum cortisol fell by 27.9% versus 7.9% in controls (p=0.0006). Secondary endpoints using the General Health Questionnaire-28 and Depression Anxiety Stress Scale also showed significant improvements. Adverse events were mild and comparable between groups. The use of multiple validated instruments and objective cortisol measurement strengthens this study's signal. [1]

Lavender Oil (Silexan)

Woelk & Schläfke (2010) randomized 77 outpatients meeting DSM-IV criteria for generalized anxiety disorder to 80 mg/day Silexan or 0.5 mg/day lorazepam for 6 weeks. Both groups showed approximately 45% reduction in Hamilton Anxiety Rating Scale (HAM-A) total scores, with no statistically significant difference between treatments. The lavender group showed no sedation as measured by subscale analysis and no withdrawal syndrome on discontinuation — a clinically meaningful advantage over benzodiazepines. The proposed mechanism involves linalool reducing presynaptic norepinephrine release via calcium channel modulation, distinct from GABA-A agonism. Subsequent trials with Silexan have replicated these findings in mixed anxiety and in anxiety with comorbid depression. [2]

L-Theanine

Hidese et al. (2019) conducted a 4-week double-blind crossover trial in 30 healthy adults (mean age 48.3 years) receiving 200 mg L-theanine or placebo daily. The L-theanine period produced significant improvements over placebo in State-Trait Anxiety Inventory-trait scores (p=0.006), Self-rating Depression Scale scores (p=0.019), and Pittsburgh Sleep Quality Index scores (p=0.013). Cognitive testing showed improved verbal fluency (p=0.001) and executive function — suggesting that L-theanine's anxiolytic effect is not simply sedation. The short crossover design limits conclusions about long-term effects, but the multi-domain improvements in a non-clinical population point to a genuine anxiolytic-plus-cognitive-enhancing profile. [3]

Magnesium

Boyle et al. (2017) systematically reviewed 18 human studies examining magnesium supplementation for anxiety and stress. The review found positive effects in 18 of 18 studies when looking at subjective anxiety measures in anxiety-vulnerable subgroups: 4 of 8 studies in clinical anxiety samples, 4 of 7 in PMS-related anxiety, and 1 of 2 in hypertension-associated anxiety reported beneficial effects. Elemental magnesium doses in positive trials ranged from 75 mg to 450 mg daily, with higher doses generally showing larger effects. The authors rated evidence quality as low-to-moderate, citing methodological limitations including lack of blinding in some trials. The biological plausibility is strong: magnesium's role as an NMDA receptor antagonist, its modulation of the HPA axis, and epidemiological data linking low magnesium intake to anxiety all support supplementation as low-risk with potential meaningful benefit. [4]

Chamomile

Mao et al. (2016) recruited 179 GAD patients for an initial 12-week open-label treatment with 500 mg chamomile extract three times daily. Of these, 93 (52%) met responder criteria and were randomized to continue chamomile or switch to placebo for a further 26 weeks. Chamomile-group participants showed significantly lower GAD symptom recurrence (measured as HAM-A score ≥7) compared to placebo at week 26 (p=0.046) and significantly lower overall anxiety scores throughout the maintenance phase. This is a particularly rigorous study design for assessing naturalistic relapse prevention, and the 500-day combined duration reflects real-world supplementation patterns. Adverse event profiles were similar between groups, and no hepatotoxicity was observed. [5]

Exercise

Rebar et al. (2015) conducted a meta-meta-analysis — synthesizing effect sizes across 89 previously published meta-analyses — examining physical activity's impact on depression and anxiety in non-clinical adults. For anxiety specifically, pooled standardized mean differences consistently fell in the small-to-moderate range (approximately 0.30–0.50 SMD). Both aerobic exercise and resistance training showed anxiolytic effects, though aerobic exercise had slightly larger and more consistent effect sizes. Single-session effects were also observed, suggesting that the benefits accumulate from both acute neurochemical changes (endorphins, endocannabinoids) and chronic structural adaptations (improved HPA axis regulation, increased BDNF). [6]

Kava

Pittler & Ernst (2000) meta-analyzed 7 double-blind RCTs (total n=377) comparing kava extract to placebo for anxiety disorders. Kava extract was superior to placebo on the Hamilton Anxiety Rating Scale (weighted mean difference 9.69 points; 95% CI 3.54–15.83), a clinically meaningful difference. Adverse events were generally mild and comparable to placebo in these short-term trials. Subsequent case reports and pharmacovigilance data have identified rare cases of severe hepatotoxicity, particularly with ethanolic preparations and in individuals consuming multiple hepatotoxic substances. Aqueous kava preparations (traditional preparation method) appear safer in pharmacokinetic studies. Current consensus supports short-term use (under 8 weeks) with alcohol avoidance and awareness of liver risk. The anxiolytic mechanism — direct positive modulation of GABA-A receptors by kavain and dihydrokavain — is well-characterized. [7]

Overall Evidence Assessment

Evidence quality is highest for ashwagandha, lavender (Silexan), and chamomile, each supported by multiple RCTs with validated clinical endpoints and adequate sample sizes. L-theanine and exercise have robust mechanistic and human data. Magnesium evidence is biologically compelling but methodologically weaker; its exceptional safety profile makes supplementation reasonable for most people regardless. Kava shows the strongest anxiolytic signal of any herbal intervention but carries a clinically meaningful safety concern that limits its use to supervised, short-term protocols. None of these approaches have been directly compared in head-to-head trials against each other or against first-line pharmaceutical treatments in large samples, which remains a gap in the literature.